QualityDipStocks / Health Care · Medical instruments
Solventum SOLV
Outside our quality screen, so we don’t track its dips. It’s 12% below its 52-week high.
Outside our quality screen, 7% under its Market Value. No fair value estimate for now: its free cash flow is negative.
- Fair value est.
- n/a
- Market Value
- $87.37price −7%
- Off 52-wk high
- −12%
- Risk vs market
- Lowbeta 0.57
5 bullish · 5 bearish See why
Key levels
Every level vs today’s $81.33
- 52-wk lowlowest close, 1 year$62.49−23.2%
- PriceFri Oct 30 close$81.33you are here
- Market Valueavg paid since Aug 5$87.37+7.4%
- 52-wk highhighest close, 1 year$92.44+13.7%
Fair value estimate
No estimate for SOLV: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much SOLV moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 2.3× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.57
- Volatility
- 30% vs 13% SPY
- Correlation SPY
- 0.24
- Correlation QQQ
- 0.09
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
GrowthDiluted EPS grew 222% to $8.88 in FY2025.
ValuationP/E of 9.9× vs a 29.2× median for the 86 Health Care companies we cover.
ProfitabilityReturn on equity of 34% over the last 12 months, up 19 points in two years.
ProfitabilityOperating margin widened to 26.2% in FY2025 from 20.6% in FY2023 (SEC filings).
ValuationTrades 6.9% below its Market Value of $87.37, the average price paid since the Aug 5 filing.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$118M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityGross margin narrowed to 53.5% in FY2025 from 57.3% in FY2023 (SEC filings).
GrowthSales grew only 0.8% a year from FY2022 to FY2025.
GrowthSales fell 0.9% over the last 12 months, below the 8.6% median for the 101 Health Care companies we cover.
QualityDoesn’t pass our quality screen: no positive free cash flow; net debt 4.3× EBITDA (limit 3×).
Who’s talking about it
Notable investors, executives, analysts and public figures on Solventum in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Medical instruments
All fundamentals
P/E 9.9 · FCF yield -0.8% · ROE 34%
Valuation
- P/E
- 9.9×Health Care median 29.2×
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −0.8%
- EV / EBITDA
- 7.3×
- Price / sales
- 1.71×
- Price / book
- 2.96×
- Market cap
- $14.2Blisted
- Enterprise value
- $18.9B
Growth
- Revenue, 12 months
- $8.3B
- Sales growth, 12 months
- −0.9%vs the 12 months before
- Sales growth, 3 yrs
- +0.8%/yrfrom FY2022
- Diluted EPS, 12 months
- $8.18
- EPS growth, last FY
- +221.7%
- Net income, 12 months
- $1.4B
- Net income growth
- +277%12 months vs before
Profitability
- Gross margin
- 54.7%
- Operating margin
- 25.0%
- Net margin
- 17.3%
- FCF margin
- −1.4%
- Return on equity
- 34%
- Return on invested capital
- 19%
Balance sheet
- Cash & short-term inv.
- $403M
- Total debt
- $5.1B
- Net cash
- −$4.7B
- Debt / equity
- 1.06×
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$118M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- −1.1%diluted shares vs a year ago
- Stock-based comp
- $167M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Solventum’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
MV $87.37
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 35 · 5 days −4.8%
The business
FCF $-0.1B · Sales +2%
- Free cash flow, 12 months−$0.1B
- Free-cash-flow yield−0.8%
- Gross margin55%
- Operating margin10%
- Return on invested capital7%
- Return on equity34%
- Sales growth (latest quarter vs year-ago quarter)+2%
- Net debt / EBITDA4.3×
Next report
Nov 5
- DateThu Nov 5, after the close
- Consensus EPS$1.38
- Year-ago EPS$1.50
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
SOLV is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.